Esperion Therapeutics (ESPR) Total Liabilities (2012 - 2026)

Esperion Therapeutics has reported Total Liabilities for 15 years, with the latest figure at $770.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 2.7% year-over-year to $770.5 million; the trailing twelve-month figure through Mar 2026 stood at $770.5 million (up 2.7% YoY), and the FY2025 full-year result was $767.9 million, up 4.82% from the prior year.
• Total Liabilities for Q1 2026 stood at $770.5 million, roughly flat from $767.9 million in the prior quarter.
• The five-year high for Total Liabilities was $815.4 million in Q3 2025, with the low at $571.7 million in Q4 2022.
• Historically, Total Liabilities has averaged $677.2 million across 5 years, with a median of $667.4 million in 2024.
• Annual changes were most pronounced in 2023 — Total Liabilities dropped 1.76% — and 2025, when it advanced 19.15%.
• Esperion Therapeutics' Total Liabilities stood at $571.7 million in 2022, then grew by 15.58% to $660.8 million in 2023, then grew by 10.86% to $732.5 million in 2024, then gained by 4.82% to $767.9 million in 2025, then increased by 0.34% to $770.5 million in 2026.
• The last three Total Liabilities figures came in at $770.5 million (Q1 2026), $767.9 million (Q4 2025), and $815.4 million (Q3 2025), per Business Quant data.